iBio, Inc. (IBIO)

1.9000 0.0000 (0.00%) At close: 04:00PM EDT

iBio, Inc.

8800 Health Science Center Parkway
Bryan, TX 77807-1107
United States
302 355 0650
https://www.ibioinc.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 26

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Martin B. Brenner D.V.M., Ph.D.	CEO & Chief Scientific Officer	577.31k	N/A	1971
Mr. Felipe Duran	Chief Financial Officer	1.07M	N/A	1980
Stephen Kilmer	Investor Relations Officer	N/A	N/A	N/A
Mr. Marc Banjak J.D.	General Counsel	N/A	N/A	N/A
Mr. Robert B. Kay	Interim Secretary & Interim Treasurer	92.69k	N/A	1940

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

Corporate governance

iBio, Inc.’s ISS governance QualityScore as of 1 April 2024 is 8. The pillar scores are Audit: 10; Board: 6; Shareholder rights: 4; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.